Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new drug reach the brain to fight Alzheimer's?

NCT ID NCT07787182

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 26, 2026 · Last updated Aug 27, 2026 · Updated 1 time

Summary

This early-stage trial evaluates the safety and tolerability of an experimental drug called LY4405094 in healthy volunteers and people with Alzheimer's disease. Researchers will measure how much of the drug enters the bloodstream and the fluid around the brain, and in Alzheimer's participants, they'll track levels of a key Alzheimer's-related protein. The study aims to understand how the drug behaves in the body and whether it might be a future treatment option.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LY4405094, an experimental drug given intravenously or under the skin
What this could lead to
If successful, this could point toward a new treatment that targets Alzheimer's-related proteins in the brain, potentially slowing the disease.
What could go wrong
This is an early Phase 1 study focused on safety and dosing, so it's too soon to know if LY4405094 will work. Possible risks include allergic reactions and side effects from the drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 68 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants must meet eligibility criteria in the ATMP screening protocol before entry into the treatment study. Exclusion Criteria: * Have known allergies to LY4405094, related compounds (including remternetug), or any components of the formulation, including LY4405094. * Have known allergic reactions to adhesive or hydrogels or a family history of adhesive skin allergies.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease amyloidosis Plaque, Amyloid

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer disease Amyloid Healthy volunteers Plaque, amyloid

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Accel Research Sites - NeuroStudies Clinical Research Unit

    Decatur, Georgia, 30030, United States

  • Charter Research

    Orlando, Florida, 32803, United States

  • Charter Research

    The Villages, Florida, 32162-2698, United States

  • Fortrea Clinical Research Unit

    Daytona Beach, Florida, 32117, United States

  • Irvine Clinical Research

    Irvine, California, 92614, United States

  • K2 Medical Research

    Maitland, Florida, 32751, United States

  • K2 Medical Research - Tampa

    Tampa, Florida, 33634, United States

  • K2 Medical Research - The Villages

    Lady Lake, Florida, 32159, United States

  • Progressive Medical Research

    Port Orange, Florida, 32127, United States

  • QUEST Research Institute

    Farmington Hills, Michigan, 48334, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.